Recent Company News

• 07:32 AM ET Jun 11, 2026
  

  Silence Therapeutics presents follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran ($6.00, 0.00)

• 05:45 PM ET Jun 03, 2026
  

  Transcript Intelligence: Silence Therapeutics at Jefferies Global Healthcare Conference ($6.41, +0.04)

• 08:53 AM ET May 28, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 28-May

• 04:59 PM ET May 27, 2026
  

  Silence Therapeutics enters Open Market Sale Agreement for up to $100M - 424B5

• 02:33 PM ET May 19, 2026
  

  Transcript Intelligence: Silence Therapeutics at H.C. Wainwright BioConnect Investor Conference ($5.92, -0.32)

• 04:10 PM ET May 18, 2026
  

  Silence Therapeutics files $300M equity shelf; enters sales agreement for up to $100M of shares with Jefferies - S-3 ($6.23, 0.00)

• 08:11 AM ET May 07, 2026
  

  Silence Therapeutics reports Q1 EPS ($0.11) vs FactSet ($0.13) [6 est, ($0.28)-(0.08)] ($7.36, 0.00)

• 10:02 AM ET Apr 23, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (178 total)

• 07:35 AM ET Mar 05, 2026
  

  Silence Therapeutics reports FY EPS ($0.63) vs FactSet ($0.91) [6 est, ($2.11)-(0.52)] ($5.78, 0.00)

• 02:00 PM ET Mar 02, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 23-Feb